Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (211-220 of 352) with videos related to

Pageof 36
Sort By:
Gut|January 9, 2015
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre studyWalter Reinisch, Julián Panés, Sunil Khurana, et al.
Journal of Crohn'S & Colitis|November 6, 2016
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND TrialWalter Reinisch, Jean-Frédéric Colombel, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-surveyPaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Gastroenterology|September 25, 2012
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel diseaseGeert D'Haens, Brian Feagan, Jean-Frédéric Colombel, et al.
Journal of Crohn'S & Colitis|December 14, 2023
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's DiseaseSéverine Vermeire, Silvio Danese, William J Sandborn, et al.
Gut|October 15, 2015
Development and validation of the Nancy histological index for UCAude Marchal-Bressenot, Julia Salleron, Camille Boulagnon-Rombi, et al.
Alimentary Pharmacology & Therapeutics|October 6, 2021
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trialsBrian G Feagan, Reena Khanna, William J Sandborn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 30, 2018
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc AnalysisJean-Frédéric Colombel, Omoniyi J Adedokun, Christopher Gasink, et al.
Gut|July 24, 2020
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developmentsKlaus Gottlieb, Marco Daperno, Keith Usiskin, et al.
Advances in Therapy|January 6, 2022
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 EraStefan Schreiber, Shomron Ben-Horin, Rieke Alten, et al.
Pageof 36

Showing results (211-220 of 352) with videos related to

Sort By:
Pageof 36
Gut|January 9, 2015
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre studyWalter Reinisch, Julián Panés, Sunil Khurana, et al.
Journal of Crohn'S & Colitis|November 6, 2016
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND TrialWalter Reinisch, Jean-Frédéric Colombel, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-surveyPaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Gastroenterology|September 25, 2012
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel diseaseGeert D'Haens, Brian Feagan, Jean-Frédéric Colombel, et al.
Journal of Crohn'S & Colitis|December 14, 2023
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's DiseaseSéverine Vermeire, Silvio Danese, William J Sandborn, et al.
Gut|October 15, 2015
Development and validation of the Nancy histological index for UCAude Marchal-Bressenot, Julia Salleron, Camille Boulagnon-Rombi, et al.
Alimentary Pharmacology & Therapeutics|October 6, 2021
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trialsBrian G Feagan, Reena Khanna, William J Sandborn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 30, 2018
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc AnalysisJean-Frédéric Colombel, Omoniyi J Adedokun, Christopher Gasink, et al.
Gut|July 24, 2020
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developmentsKlaus Gottlieb, Marco Daperno, Keith Usiskin, et al.
Advances in Therapy|January 6, 2022
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 EraStefan Schreiber, Shomron Ben-Horin, Rieke Alten, et al.
Pageof 36